Connect with others who understand.

sign up log in
Resources
About MyMyelomaTeam

Connect with others who understand.

sign up log in
Resources
About MyMyelomaTeam

Solitary Plasmacytoma vs. Myeloma: How Are They Different?

Posted on January 11, 2022
Medically reviewed by
Todd Gersten, M.D.
Article written by
Aminah Wali, Ph.D.

Solitary plasmacytoma and multiple myeloma are types of cancer that form from plasma cells. Plasma cells are white blood cells that work as part of the immune system. Normally, these cells produce antibodies, which are proteins that help recognize and fight infection. However, genetic defects can occur that cause plasma cells to multiply uncontrollably, giving rise to a group of diseases known as plasma cell neoplasms (plasma cell cancers) such as solitary plasmacytoma and multiple myeloma.

Solitary plasmacytoma and multiple myeloma are rare diseases and have several distinguishing features.

What Is Multiple Myeloma?

Multiple myeloma is the most common plasma cell cancer. It forms when abnormal plasma cells form tumors in the bone marrow. The cancer cells make an abnormally large amount of an antibody called monoclonal immunoglobulin or M protein, which can’t fight infection properly. M protein then accumulates in the body.

Multiple myeloma is a rare disease overall, accounting for about 1 percent of all cancer cases with approximately 30,000 cases per year.

What Is Solitary Plasmacytoma?

Solitary plasmacytoma is also formed from abnormal plasma cells. Unlike multiple myeloma, however, solitary plasmacytoma is characterized by a plasma cell tumor that grows in a single location rather than in multiple bone marrow sites throughout the body. The most common location of the tumor is bone, and solitary plasmacytoma is often called solitary plasmacytoma of bone. It is a much rarer disease than multiple myeloma, with fewer than 450 cases per year.

Symptoms of Solitary Plasmacytoma vs. Multiple Myeloma

Common signs of multiple myeloma are often referred to using the abbreviation CRAB, which stands for:

  • Calcium in high levels
  • Renal (kidney) failure
  • Anemia (low red blood cell count)
  • Bone lesions (tumors)

Other signs and symptoms of multiple myeloma include:

  • Bone pain or fractures
  • Fatigue
  • Frequent infections

In contrast to multiple myeloma, solitary plasmacytoma does not cause CRAB symptoms. Solitary plasmacytoma has overall fewer symptoms, which may include:

  • Bone pain
  • Sensory and movement defects, in cases when the spinal cord is affected

Diagnosis of Solitary Plasmacytoma vs. Multiple Myeloma

To diagnose multiple myeloma or solitary plasmacytoma, doctors perform a series of laboratory tests to look for features of the disease.

Tests for Multiple Myeloma

Your doctor may use different tests to look for the signs and symptoms of multiple myeloma.

CRAB Criteria

High levels of calcium, renal failure, and anemia can be determined using a blood test or urine test. The presence of bony lesions can be confirmed using imaging techniques such as X-ray, computerized tomography (CT) scan, or positron emission tomography (PET) combined with a CT scan.

M Protein Levels

Multiple myeloma and plasmacytoma often cause high levels of an antibody referred to as M protein. Accumulation of M protein can be detected using a blood test.

Cancer Cells in Bone Marrow

Finding that abnormal plasma cells make up at least 10 percent of cells in the bone marrow can lead to a diagnosis of multiple myeloma. To make this determination, your doctor may do a bone marrow biopsy, in which they obtain and analyze a bone marrow sample.

Tests for Solitary Plasmacytoma

To distinguish solitary plasmacytoma from multiple myeloma, the doctor must confirm abnormal bone marrow and the absence of CRAB symptoms. Doctors must also examine a person for additional evidence of disease. For instance, a single tumor, generally in the bone, must be observed to confirm diagnosis of solitary plasmacytoma. Bone lesions are detected using X-ray, CT, or PET imaging technologies.

Treatment Options for Solitary Plasmacytoma vs. Multiple Myeloma

The treatment options for the two conditions differ.

Treatment for Multiple Myeloma

There are several options for treating multiple myeloma. The exact treatment recommended by a doctor depends on individual factors such as your age and stage of the disease.

Chemotherapy

Initial treatment of multiple myeloma generally involves chemotherapy to kill cancer cells. There are several chemotherapy drugs approved to treat multiple myeloma, and these regimens generally include combinations of different drugs, such as Velcade (bortezomib) and Cytoxan (cyclophosphamide).

Other Drug Therapy

In addition to chemotherapeutic drugs, other types of drugs are often used to treat multiple myeloma. These drugs include immunomodulators such as Revlimid (lenalidomide), which are drugs that affect how the immune system works. Corticosteroid drugs might also be prescribed, often in combination with chemotherapy.

Stem Cell Transplant

Also called a bone marrow transplant, a stem cell transplant when used for myeloma treatment involves replacing the cells in a person’s bone marrow with healthy cells after high doses of the chemotherapy drug Melphalan destroy the bone marrow (and any myeloma living there). There are two types of stem cell transplants. An autologous stem cell transplant, which is more commonly recommended, means the stem cells come from the person’s body. The other option is an allogeneic stem cell transplant, in which stem cells come from a donor. Allogeneic stem cell transplant is rarely used to treat myeloma.

Treatment for Solitary Plasmacytoma

Radiation therapy is the standard treatment for solitary plasmacytoma. Because only a single tumor is involved, radiation is generally effective at treating the disease. Surgery may also be recommended in some cases.

Outlook for Solitary Plasmacytoma vs. Multiple Myeloma

The five-year survival rate for solitary plasmacytoma is as high as 70 percent, although it can vary depending on the location of the tumor and the type of treatment received. Solitary plasmacytoma is potentially curable with standard treatments, but solitary plasmacytoma can develop into multiple myeloma. In those cases, a person affected would require additional treatment.

Relative to solitary plasmacytoma, multiple myeloma has an overall worse prognosis (outlook). After initial treatment success, most patients relapse, and cancer will reappear after time. The five-year survival rate is approximately 50 percent. Newer, more effective treatments are being developed to improve the prognosis for people diagnosed with multiple myeloma.

Talk With Others Who Understand

MyMyelomaTeam is the social network for people with multiple myeloma. On MyMyelomaTeam, more than 13,000 members come together to ask questions, give advice, and share their stories with others who understand life with myeloma.

Are you living with multiple myeloma or solitary plasmacytoma? Share your experiences in the comments below, or start a conversation by posting on your Activities page.

All updates must be accompanied by text or a picture.
Todd Gersten, M.D. is a hematologist-oncologist at the Florida Cancer Specialists & Research Institute in Wellington, Florida. Review provided by VeriMed Healthcare Network. Learn more about him here.
Aminah Wali, Ph.D. received her doctorate in genetics and molecular biology from the University of North Carolina at Chapel Hill. Learn more about her here.

Related articles

M protein is a molecule that is not normally made by the body. The “M” technically stands for “...

The Role of M Protein in Myeloma

M protein is a molecule that is not normally made by the body. The “M” technically stands for “...
If you or a loved one has been diagnosed with multiple myeloma, treatments are available. Take...

How Much Do You Know About Myeloma Treatments?

If you or a loved one has been diagnosed with multiple myeloma, treatments are available. Take...
By: Robert Preidt, HealthDay Reporter WEDNESDAY, March 27, 2019 (HealthDay News) -- The chances...

Ancestry Matters When Seeking Matched Bone Marrow Donors

By: Robert Preidt, HealthDay Reporter WEDNESDAY, March 27, 2019 (HealthDay News) -- The chances...
By Steven Reinberg, HealthDay Reporter TUESDAY, Jan. 8, 2019 (HealthDay News) -- Over the past 25...

U.S. Cancer Deaths Continue to Decline

By Steven Reinberg, HealthDay Reporter TUESDAY, Jan. 8, 2019 (HealthDay News) -- Over the past 25...
By Dennis Thompson, HealthDay Reporter MONDAY, June 5, 2017 (HealthDay News) -- Genetically...

Gene-Based Therapy May Thwart a Tough Blood Cancer

By Dennis Thompson, HealthDay Reporter MONDAY, June 5, 2017 (HealthDay News) -- Genetically...

Recent articles

Working while undergoing treatment for multiple myeloma is a personal decision with several...

Working With Multiple Myeloma

Working while undergoing treatment for multiple myeloma is a personal decision with several...
Thanks to years of cancer research and public-health messaging, most people understand that...

Smoking and Multiple Myeloma

Thanks to years of cancer research and public-health messaging, most people understand that...
Around 63 percent of people newly diagnosed with myeloma are also living with — or have a history...

Understanding Heart Disease and Myeloma Treatment

Around 63 percent of people newly diagnosed with myeloma are also living with — or have a history...
Multiple myeloma is a cancer in which white blood cells called plasma cells develop abnormalities...

Myeloma and Ethnicity: Is Race a Risk Factor in Multiple Myeloma?

Multiple myeloma is a cancer in which white blood cells called plasma cells develop abnormalities...
Feelings of worry, fear, and anxiety are common when living with cancer such as myeloma. In fact,...

Managing Anxiety and Myeloma

Feelings of worry, fear, and anxiety are common when living with cancer such as myeloma. In fact,...
People with multiple myeloma at any stage can benefit from palliative care. This type of care can...

Palliative Care: Improving Quality of Life With Myeloma at Any Stage

People with multiple myeloma at any stage can benefit from palliative care. This type of care can...
MyMyelomaTeam My myeloma Team

Thank you for subscribing!

Become a member to get even more:

sign up for free

close